Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 4, 2011, Pages 386-393

  Mei, Yifang ^a   Jin, Hong ^b   Tian, Wei ^a   Wang, Hao ^a   Wang, Han ^c   Zhao, Yanping ^a   Zhang, Zhiyi ^a   Meng, Fanchao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Monocrotaline; Nitric oxide; Pulmonary arterial hypertension; Urantide

Indexed keywords

MONOCROTALINE; N(G) NITROARGININE METHYL ESTER; URANTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASODILATATION;

ANIMALS; HEMODYNAMICS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NITRIC OXIDE; ORGAN SIZE; PEPTIDE FRAGMENTS; PULMONARY ARTERY; RATS; RATS, WISTAR; UROTENSINS; VASODILATION;

EID: 79956097610     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.03.003     Document Type: Article

References (33)

1. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-349.
2. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.
3. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997, 336:111-117.
4. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
5. Confalonieri M., Kodric M., Longo C., Vassallo F.G. Bosentan for chronic thromboembolic pulmonary hypertension. Expert Rev Cardiovasc Ther 2009, 7:1503-1512.
6. Schroll S., Arzt M., Sebah D., Nuchterlein M., Blumberg F., Pfeifer M. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan. Respir Physiol Neurobiol 2010, 170:32-36.
7. Valerio C.J., Coghlan J.G. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009, 5:607-619.
8. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-286.
9. Richards A.M., Charles C. Urotensin II in the cardiovascular system. Peptides 2004, 25:1795-1802.
10. Maguire J.J., Davenport A.P. Is urotensin-II the new endothelin?. Br J Pharmacol 2002, 137:579-588.
11. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:141-149.
12. Morimoto R., Satoh F., Murakami O., Totsune K., Arai Y., Suzuki T., et al. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides 2008, 29:873-880.
13. Elshourbagy N.A., Douglas S.A., Shabon U., Harrison S., Duddy G., Sechler J.L., et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002, 136:9-22.
14. MacLean M.R., Alexander D., Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000, 130:201-204.
15. Simpson C.M., Smolich J.J., Shekerdemian L.S., Penny D.J. Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. Pediatr Res 2010, 67:150-157.
16. Djordjevic T., BelAiba R.S., Bonello S., Pfeilschifter J., Hess J., Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005, 25:519-525.
17. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280:H925-H928.
18. Djordjevic T., Gorlach A. Urotensin-II in the lung: a matter for vascular remodelling and pulmonary hypertension?. Thromb Haemost 2007, 98:952-962.
19. Hongo M., Sentianin E.M., Tanaka N., Mao L., McKirnan M.D., Clark R.G., et al. Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction. J Card Fail 1998, 4:213-224.
20. Hongo M., Ryoke T., Schoenfeld J., Hunter J., Dalton N., Clark R., et al. Effects of growth hormone on cardiac dysfunction and gene expression in genetic murine dilated cardiomyopathy. Basic Res Cardiol 2000, 95:431-441.
21. Mathew R., Gloster E.S., Sundararajan T., Thompson C.I., Zeballos G.A., Gewitz M.H. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. J Appl Physiol 1997, 82:1493-1498.
22. Cowan K.N., Heilbut A., Humpl T., Lam C., Ito S., Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000, 6:698-702.
23. Papadopoulos P., Bousette N., Giaid A. Urotensin-II and cardiovascular remodeling. Peptides 2008, 29:764-769.
24. Maryanoff B.E., Kinney W.A. Urotensin-II receptor modulators as potential drugs. J Med Chem 2010, 53:2695-2708.
25. Lawson E.C., Luci D.K., Ghosh S., Kinney W.A., Reynolds C.H., Qi J., et al. Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem 2009, 52:7432-7445.
26. Clozel M., Hess P., Rey M., Iglarz M., Binkert C., Qiu C. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood) 2006, 231:967-973.
27. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009, 53:1573-1619.
28. Watanabe T., Kanome T., Miyazaki A., Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 2006, 29(6):375-387.
29. Haworth S.G. Role of the endothelium in pulmonary arterial hypertension. Vascul Pharmacol 2006, 45:317-325.
30. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333(4):214-221.
31. Camarda V., Song W., Marzola E., Spagnol M., Guerrini R., Salvadori S., et al. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004, 498:83-86.
32. Blatter L.A., Taha Z., Mesaros S., Shacklock P.S., Wier W.G., Malinski T. Simultaneous measurements of Ca2+ and nitric oxide in bradykinin-stimulated vascular endothelial cells. Circ Res 1995, 76:922-924.
33. Puikuan K., Chunyu Z., Jin F., Chaoshu T., Junbao D. Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Heart Vessels 2006, 21:169-179.